An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Contact:

NCT Number:

Protocol:

AAAR6732

Study Status:

Closed to Accrual, Study Active

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study you will receive either BGB-3111 or the standard chemotherapy treatment bendamustine plus rituximab (B+R).

Are you Eligible? (Inclusion Criteria)

  • To be eligible for this trial, participants must:
  • Do you have a diagnosis of CLL or SLL?
  • Are you at least 18 years old?
  • Do you have adequate organ function?
  • Do you have a life expectancy of at lease 6 months?

Specialty Area(s)

Chronic Lymphocytic Leukemia

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032